Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients
Status:
Terminated
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
This is a pilot study to determine if extended release Envarsus at an optimal level is just
as effective as more invasive standard therapies for subclinical (mild) AMR (antibody
mediated rejection) in kidney transplant patients. Subjects will be randomized to either
conversion to Envarsus XR (extended release); or, to a standard of care regimen of plasma
exchange/IVIG (intravenous immunoglobulin)/rituximab treatments.